Cardoz AB, a Stockholm, Sweden-based developer of pharmaceutical products in the field of cardiovascular inflammation, has held a second closing of its SEK124m series A financing round (approximately $ 17m and € 13m).
The financing was led by Forbion Capital Partners, with participation from new investors YSIOS Capital Partners and Industrifonden and existing backer HealthCap.
Proceeds from the current financing will enable Cardoz to accelerate its phase II clinical program for prevention of growth and rupture of ab-dominal aortic aneurysms (AAA).
In conjunction with the funding, Dr. Jonas Brambeck of Industrifonden, will join the board of directors of Cardoz.
FinSMEs
16/09/2010